Ex-Meditech CEO to head WA firm Acuron
Monday, 29 November, 2004
Three months after being forced to step down as CEO of Melbourne biotech Meditech (ASX:MTR) after a shareholder stoush, expat South African Chris Carter has been appointed CEO of Western Australian minerals-explorer-turned-biotech Acuron (ASX:AVP).
Acuron's two wholly owned subsidiaries, Vacutex and Pro-Tex, manufacture and distribute a range of advanced wound care products. The company's flagship product -- capillary action dressing Vacutex -- has been approved by the TGA and the UK's National Health Scheme, and is also distributed in the Middle East and parts of South-East Asia. Acuron is in the process of submitting for approval from the US Food and Drug Administration (FDA).
Carter will take over from George Cameron-Dow as Acuron's managing director, and from Johann Fourie as CEO of both Vacutex and Pro-Tex. Both Cameron-Dow and Fourie will move to non-executive roles.
"We are very pleased to announce Chris's appointment as we accelerate the global roll-out of Acuron's advanced wound care product range." said Acuron chairman, Patrick O'Connor in a statement. "Chris has a strong track record in developing healthcare businesses and in securing the support of institutional investors."
Immune cell boost could enable lasting vaccine protection
A research team has found a promising new way to enhance the effectiveness of vaccines by tapping...
Genes influence when babies start walking
Genetics accounts for about a quarter of the differences in when children take their first steps,...
Novel glycopeptide antibiotic candidate shows promise
Researchers have discovered a new type of glycopeptide antibiotic known as saarvienin A, found to...
